Titan Biotech Ltd (TITANBIO) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Titan Biotech Ltd on NSE and BSE, with an AI summary of each filing.
Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/11/2026 ,inter alia, to consider and approve Unaudited Financial Results for ....
Intimation · 05 Nov 2026, 5:30 am
Titan Biotech Board to Consider Q2 Results on 5th Nov'26 Titan Biotech Limited has scheduled a Board of Directors meeting on 5th Nov'26 to consider and approve the unaudited standalone and consolidated financial results for the second quarter and half-year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the trading window for dealing in company securities has been closed since 1st Oct'26 and will reopen 48 hours after the declaration of the board meeting outcomes.
Allotment of 1,03,29,625 Fully Paid Up Bonus Equity Shares of Rs. 2/- each to Shareholder holding shares on 23rd October, 2026 (record Date)
Bonus Issue · 26 Oct 2026, 3:40 pm
Titan Biotech Approves 1:4 Bonus Share Allotment Titan Biotech Limited approved the allotment of 1,03,29,625 fully paid-up bonus equity shares of Rs. 2/- each on 26th Oct'26. The bonus shares were issued in a 1:4 ratio (one new equity share for every four existing shares) to eligible shareholders registered as of the record date, 23rd Oct'26. Consequently, the company's paid-up equity share capital expanded from Rs. 8,26,37,000 (4,13,18,500 shares) pre-issue to Rs. 10,32,96,250 (5,16,48,125 shares) post-issue. Shares will be credited within statutory time limits.
The Company has fixed record date as Friday, October 23, 2026 for ascertaining the eligibility of Shareholders entitled for allotment of Bonus Equity Shares in the ratio of 1:4 and deemed ....
Bonus Issue · 09 Oct 2026, 10:17 pm
Titan Biotech Sets Record Date for 1:4 Bonus Issue Titan Biotech has fixed 23rd Oct'26 as the record date to determine shareholder eligibility for its 1:4 bonus share issue, following shareholder approval and in-principle clearance from BSE. The company will issue 1,03,29,625 fully paid-up bonus equity shares of face value Rs. 2 each. The deemed date of allotment is set for 26th Oct'26, with the newly allotted bonus shares scheduled to commence trading on 27th Oct'26.
Alteration of the Clause 5 i.e. Capital Clause of the Memorandum of Association (MOA) of the Company
Others (Uncategorized) · 30 Sept 2026, 9:54 pm
Titan Biotech Increases Authorized Share Capital to Rs 10.40 Crore Titan Biotech Limited's members approved an increase in authorized share capital from Rs. 10.00 crore to Rs. 10.40 crore at its 34th Annual General Meeting held on 29th Sep'26. The capital expansion involves creating 20,00,000 new equity shares of Rs. 2/- each, bringing total equity shares to 5,20,00,000 from 5,00,00,000. Consequently, the company has altered Clause 5 (Capital Clause) of its Memorandum of Association to reflect the updated authorized capital structure.
Voting results and Scrutinizers Report for 34th Annual General Meeting of the Company
Annual General Meeting · 30 Sept 2026, 9:13 pm
Proceedings of 34th Annual General Meeting of Titan Biotech Limited
Annual General Meeting · 30 Sept 2026, 12:13 am
The Company has sent Letters to those members who have not registered their email address with the Company/RTA/ Depository providing a weblink including exact path of Website to access ....
Annual General Meeting · 05 Sept 2026, 11:39 pm
Notice of 34th Annual General Meeting of the Company scheduled to be held on Tuesday, September 29, 2026 at 03:00 P.M.(IST) through VC/OAVM
Annual General Meeting · 05 Sept 2026, 9:18 pm
34th Annual Report of the Company for Financial Year 2025-26
Others (Uncategorized) · 05 Sept 2026, 9:12 pm
Intimation of record date for the purpose of Dividend to the members of the Company for FY 2025-26.
Dividend · 03 Sept 2026, 6:12 pm
Titan Biotech Sets Record Date for FY26 Final Dividend of Rs. 0.50 Per Share Titan Biotech Limited has fixed 22nd Sep'26 as the record date to determine shareholder eligibility for a final dividend of Rs. 0.50 per equity share (face value Rs. 2) for FY26. The dividend recommendation, initially made by the Board on 30th May'26, remains subject to shareholder approval at the company's 34th Annual General Meeting. If approved, the payout will be executed post-AGM, subject to applicable tax deductions at source.
The 34th Annual General Meeting of the Company scheduled to be held on September 29, 2026 through VC/ OAVM and the Company accordingly fixed Record Date, Book Closure Date and E-Voting Date
Annual General Meeting · 03 Sept 2026, 6:02 pm
Recommended the Issuance of Bonus Issue, subject to shareholders approval and any other applicable regulatory and statutory approval, in the ratio of 1:4 .i.e. 1(one) new Fully paid up ....
Bonus Issue · 03 Sept 2026, 5:51 pm
Recommended Issuance of Bonus Shares, subject to shareholders approval and any other applicable regulatory and statutory approval, in ratio of 1:4 i.e. 1(one) new fully paid up Equity Shares ....
Outcome · 03 Sept 2026, 5:44 pm
Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/09/2026 ,inter alia, to consider and approve 1. the proposal of bonus issue, ....
Intimation · 31 Aug 2026, 9:33 pm
Board Meeting Outcome For Unaudited Financial Results For Quarter Ended June 30, 2026
Outcome · 13 Aug 2026, 9:25 pm
Titan Biotech Reports Strong Q1 FY27 Results Titan Biotech reported strong standalone results for Q1 FY27 (ended 30 Jun'26), with net profit up 53.5% YoY to ₹945.59 lakhs and revenue from operations rising 27.2% YoY to ₹5,916.66 lakhs. On a QoQ basis, net profit grew 44.3%. Consolidated net profit for the quarter was ₹1,085.68 lakhs, up 58.2% YoY. The Board approved these unaudited financial results on 13 Aug'26. Basic EPS for the quarter stood at ₹2.29 on a standalone basis and ₹2.63 on a consolidated basis.
Unaudited Financial Results along with the limited review report from the statutory Auditor of the Company for the quarter ended June 2026
Financial Result · 13 Aug 2026, 9:18 pm
Titan Biotech Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 5,917 (+27.2% YoY | +21.2% QoQ) ■ EBITDA: 1,249 (+42.9% YoY | +28.6% QoQ) ■ EBITDA Margin (%): 21.1 (+231 bps YoY | +122 bps QoQ) ■ PAT: 1,086 (+58.2% YoY | +61.3% QoQ) ■ EPS (INR): 2.63 (-68.3% YoY | +61.3% QoQ)
Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2026 ,inter alia, to consider and approve the standalone and consolidated ....
Intimation · 13 Aug 2026, 5:30 am
Titan Biotech Board Meeting on Aug 13, '26 for Q1 Results Titan Biotech Limited's Board of Directors will meet on 13 Aug '26 to consider and approve the unaudited standalone and consolidated financial results for the first quarter ended 30 Jun '26. The trading window for designated persons has been closed from 01 Jul '26 and will reopen 48 hours after the results are declared on 13 Aug '26.
Intimation for loss of shares by shareholder which have already been transferred earlier to Investor Education Protection Fund.
Press Release · 25 Jun 2026, 4:46 pm
Titan Biotech Reports Loss of Share Certificates Previously Transferred to IEPF Titan Biotech Ltd. informed BSE on 25-Jun'26 about the loss of 300 share certificates (Folio No. 0014196) belonging to shareholder Dhiren B Sanghvi. These shares had been previously transferred to the Investor Education and Protection Fund (IEPF) and are now being claimed. The company has issued a public notice for the loss and will process a duplicate issue through IEPF if no objections are received within 15 days.
Intimation for re-appointment of Cost Auditor of the Company
Change in Auditor · 30 May 2026, 9:34 pm
Titan Biotech Re-appoints Cost Auditor for FY 2026-2027 Titan Biotech's Board of Directors approved the re-appointment of M/s Sanjay Kumar Garg & Associates as the Cost Auditor for FY 2026-2027 in its meeting on 30th May'26. The decision was based on the Audit Committee's recommendation. The appointment is subject to shareholder ratification of remuneration at the upcoming Annual General Meeting. This action ensures continuity in the company's cost audit function.
The Board of Director of the Company has recommended a dividend of Rs. 0.50 paisa per Equity Share
Dividend · 30 May 2026, 9:29 pm
Titan Biotech FY26 Results: Profit Up 50% YoY, Recommends Dividend Titan Biotech reported standalone FY26 results with total income rising 32% YoY to ₹21,160.05 lakhs and net profit growing 50% YoY to ₹2,744.72 lakhs. For Q4FY26, revenue was ₹4,883.35 lakhs and net profit was ₹655.57 lakhs. The Board recommended a dividend of ₹0.50 per equity share (face value ₹2), subject to shareholder approval. The company also re-appointed M/s Sanjay Kumar Garg & Associates as its Cost Auditor for FY27. Basic EPS for FY26 stood at ₹6.64.
Audited Financial Results for March 31, 2026
Financial Result · 30 May 2026, 9:25 pm
Titan Biotech FY26 Results: Profit Grows, Recommends Dividend Titan Biotech reported standalone FY26 results with total income at ₹21,160.05 lakhs, up 32.0% YoY, and PAT at ₹2,744.72 lakhs, up 50.2% YoY. For Q4 FY26, total income stood at ₹5,093.99 lakhs (+39.4% YoY, -11.8% QoQ) with PAT at ₹655.57 lakhs (+74.1% YoY, -16.7% QoQ). The Board recommended a dividend of ₹0.50 per equity share (face value ₹2), subject to shareholder approval. The company also completed a 1:5 stock subdivision effective 20th Feb'26.
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors, at its meeting held today i.e. ....
Outcome · 30 May 2026, 9:18 pm
Titan Biotech Ltd - Financial Result for the Quarter ended 31st Mar'26 (Consolidated, INR Lakh) ■ Revenue: 4,883 (+38.9% YoY | -13.6% QoQ) ■ EBITDA: 971 (+112.5% YoY | -10.3% QoQ) ■ EBITDA Margin (%): 19.9 (+689 bps YoY | +72 bps QoQ) ■ PAT: 673 (+66.3% YoY | -21.1% QoQ) ■ EPS (INR): 1.63 (+66.3% YoY | -20.9% QoQ)
Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2026 ,inter alia, to consider and approve the audited financial results ....
Intimation · 30 May 2026, 5:30 am
Titan Biotech Board Meeting on May 30 to Approve FY26 Results and Dividend Titan Biotech has scheduled a Board of Directors meeting for 30th May'26 to consider and approve its audited standalone and consolidated financial results for the financial year ending 31st Mar'26. The board will also consider and recommend a dividend, if any, for FY26. In line with SEBI regulations, the trading window for designated persons has been closed from 1st Apr'26 and will reopen 48 hours after the meeting's outcome is declared.
Second 100 days Campaign under Saksham Niveshak Yojna
Others (Uncategorized) · 06 May 2026, 11:30 pm
Titan Biotech Launches "Saksham Niveshak" Campaign for Unclaimed Dividends Titan Biotech announced its participation in the second "Saksham Niveshak" 100-day campaign, running from 01 Apr'26 to 09 Jul'26. This initiative, mandated by the Investor's Education and Protection Fund Authority (IEPFA), aims to help shareholders claim unpaid/unclaimed dividends. The company is urging investors to update their KYC details, including PAN, nomination, and bank account information, to facilitate the electronic payment of dividends. Required forms are available on the company website, with a submission deadline of 09 Jul'26.
Newspaper publication regarding special window for re-lodgement of transfer request and dematerialisation of physical shares.
Press Release · 06 May 2026, 5:01 pm
Titan Biotech Opens Special Window for Physical Share Dematerialization Titan Biotech announced a special one-year window for shareholders to re-lodge transfer requests and dematerialize physical shares. This initiative, pursuant to a SEBI circular, runs from 5 Feb'26 to 4 Feb'27. The window facilitates the processing of transfer and dematerialization requests for physical shares, including those previously rejected. Newspaper advertisements regarding this were published on 6 May'26 in the Financial Express and Naya India.